Canadá - inglês - Health Canada

leadiant biosciences, inc - procarbazine (procarbazine hydrochloride) - capsule - 50mg - procarbazine (procarbazine hydrochloride) 50mg - antineoplastic agents

Canadá - inglês - Health Canada

tersera therapeutics llc - goserelin (goserelin acetate) - implant - 3.6mg - goserelin (goserelin acetate) 3.6mg - gonadotropins and antigonadotropins

Canadá - inglês - Health Canada

hospira healthcare ulc - oxaliplatin - powder for solution - 50mg - oxaliplatin 50mg - antineoplastic agents

Canadá - inglês - Health Canada

hospira healthcare ulc - oxaliplatin - powder for solution - 100mg - oxaliplatin 100mg - antineoplastic agents

Estados Unidos - inglês - NLM (National Library of Medicine)

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml

Estados Unidos - inglês - NLM (National Library of Medicine)

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g

Estados Unidos - inglês - NLM (National Library of Medicine)

padagis us llc - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml - podofilox topical solution 0.5% is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions ). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called "bowenoid papulosis") is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox topical solution 0.5%. podofilox topical solution 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.

Estados Unidos - inglês - NLM (National Library of Medicine)

physicians total care, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml - podofilox 0.5% solution is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called “bowenoid papulosis”) is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox 0.5% solution. podofilox 0.5% solution is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.